Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Vor Biopharma secured $110 million in July to move its CD33-inactivated cell therapy into clinical testing. The company's hope is that patients with high-risk acute myeloid leukemia who receive transplants of the gene-edited stem cells will then better tolerate therapies designed to destroy cells expressing CD33, an antigen found in abundance on leukemic blasts. ©2020 American Association for Cancer Research.


Vor Nets $110m to Make Anti-CD33 Drugs Safer. Cancer discovery. 2020 Sep;10(9):1248-1249

PMID: 32747379

View Full Text